Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication

Renal cell carcinoma (RCC) is the common type of kidney cancer linked to alteration of lipid, glucose, and amino acid metabolism. Early stage RCC has prognosis with overall 5-year survival rate of 90%, and the RCC has unfavorable prognosis when the disease metastasizes. Loss of or carrying mutated t...

Full description

Saved in:
Bibliographic Details
Main Authors: Ghulam Raza, Kareem Khan
Format: Article
Language:English
Published: Asian Medical Press Ltd.(H.K.) 2025-03-01
Series:Annals of Urologic Oncology
Subjects:
Online Access:https://auo.asmepress.com/articles/new-64-36.html
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850095445258272768
author Ghulam Raza
Kareem Khan
author_facet Ghulam Raza
Kareem Khan
author_sort Ghulam Raza
collection DOAJ
description Renal cell carcinoma (RCC) is the common type of kidney cancer linked to alteration of lipid, glucose, and amino acid metabolism. Early stage RCC has prognosis with overall 5-year survival rate of 90%, and the RCC has unfavorable prognosis when the disease metastasizes. Loss of or carrying mutated tumor suppressor gene VHL is the cause of HIF elevation leading to initiation of RCC. The epidermal growth factor receptor (EGFR) is a transmembrane protein, contributes to crucial role in cellular expansion, multiplication, and survival. EGFR overexpression in RCC is 40-80% and EGFR signaling pathway is dysregulated in various malignancies including RCC. RCC is not primarily governed by EGFR. Several critical pathways are dysregulated in RCC, that are mediated by EGFR including VHL-HIF pathway, PI3K/Akt/mTOR signalig, and VEGF-induced angiogenesis leading to tumor growth and RCC progression. Inhibition of angiogenesis was observed upon EGFR blockade. EGFR overexpression in RCC is linked to higher tumor grade, metastatic disease, worse prognosis, poor survival, and resistance to therapies. EGFR-mediated RCC progression is either due to higher EGF expression or elevation of EGFR in the cell membrane. Therefore, targeting EGFR in RCC is a robust strategy to inhibit EGFR-driven disease progression. In this review, we pointed out the potential role of EGFR in RCC and associated molecular mechanisms that are closely related to initiation and progression of RCC. Herein, we also highlighted the therapeutic implication of targeting the EGFR in RCC.
format Article
id doaj-art-3d1313e9821b4cc79ec3fc4795195afb
institution DOAJ
issn 2617-7765
2617-7773
language English
publishDate 2025-03-01
publisher Asian Medical Press Ltd.(H.K.)
record_format Article
series Annals of Urologic Oncology
spelling doaj-art-3d1313e9821b4cc79ec3fc4795195afb2025-08-20T02:41:26ZengAsian Medical Press Ltd.(H.K.)Annals of Urologic Oncology2617-77652617-77732025-03-0181505810.32948/auo.2025.03.18Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic ImplicationGhulam Raza0Kareem Khan1Department of Pathology, King Edward Medical University/Mayo Hospital, Lahore, Pakistan.Medical College, Aga Khan University, Karachi, Pakistan.Renal cell carcinoma (RCC) is the common type of kidney cancer linked to alteration of lipid, glucose, and amino acid metabolism. Early stage RCC has prognosis with overall 5-year survival rate of 90%, and the RCC has unfavorable prognosis when the disease metastasizes. Loss of or carrying mutated tumor suppressor gene VHL is the cause of HIF elevation leading to initiation of RCC. The epidermal growth factor receptor (EGFR) is a transmembrane protein, contributes to crucial role in cellular expansion, multiplication, and survival. EGFR overexpression in RCC is 40-80% and EGFR signaling pathway is dysregulated in various malignancies including RCC. RCC is not primarily governed by EGFR. Several critical pathways are dysregulated in RCC, that are mediated by EGFR including VHL-HIF pathway, PI3K/Akt/mTOR signalig, and VEGF-induced angiogenesis leading to tumor growth and RCC progression. Inhibition of angiogenesis was observed upon EGFR blockade. EGFR overexpression in RCC is linked to higher tumor grade, metastatic disease, worse prognosis, poor survival, and resistance to therapies. EGFR-mediated RCC progression is either due to higher EGF expression or elevation of EGFR in the cell membrane. Therefore, targeting EGFR in RCC is a robust strategy to inhibit EGFR-driven disease progression. In this review, we pointed out the potential role of EGFR in RCC and associated molecular mechanisms that are closely related to initiation and progression of RCC. Herein, we also highlighted the therapeutic implication of targeting the EGFR in RCC.https://auo.asmepress.com/articles/new-64-36.htmlrenal cell carcinomaepidermal growth factor receptorvhl-hif pathwaypi3k/akt/mtorvegfangiogenesis
spellingShingle Ghulam Raza
Kareem Khan
Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
Annals of Urologic Oncology
renal cell carcinoma
epidermal growth factor receptor
vhl-hif pathway
pi3k/akt/mtor
vegf
angiogenesis
title Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
title_full Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
title_fullStr Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
title_full_unstemmed Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
title_short Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
title_sort involvement of epidermal growth factor receptor egfr signaling in renal cell carcinoma progression and therapeutic implication
topic renal cell carcinoma
epidermal growth factor receptor
vhl-hif pathway
pi3k/akt/mtor
vegf
angiogenesis
url https://auo.asmepress.com/articles/new-64-36.html
work_keys_str_mv AT ghulamraza involvementofepidermalgrowthfactorreceptoregfrsignalinginrenalcellcarcinomaprogressionandtherapeuticimplication
AT kareemkhan involvementofepidermalgrowthfactorreceptoregfrsignalinginrenalcellcarcinomaprogressionandtherapeuticimplication